Antibody-targeted radiation cancer therapy

Several monoclonal antibodies are now approved for cancer therapy, such as rituximab, an anti-CD20 monoclonal antibody for the treatment of B-cell non-Hodgkin's lymphoma. Such 'naked' antibodies can recruit the body's immune effector mechanisms to kill cells expressing the target...

Full description

Saved in:
Bibliographic Details
Published inNature reviews. Drug discovery Vol. 3; no. 6; pp. 488 - 499
Main Authors Brechbiel, Martin W, Milenic, Diane E, Brady, Erik D
Format Journal Article
LanguageEnglish
Published England Nature Publishing Group 01.06.2004
Subjects
Animals
Antibodies, Monoclonal - metabolism
Antibodies, Neoplasm - metabolism
Cancer
Care and treatment
Clinical Trials as Topic - statistics & numerical data
Drug Delivery Systems - methods
Humans
Methods
Neoplasms - metabolism
Neoplasms - radiotherapy
Radioimmunotherapy
Online AccessGet full text

Cover

More Information
Summary:Several monoclonal antibodies are now approved for cancer therapy, such as rituximab, an anti-CD20 monoclonal antibody for the treatment of B-cell non-Hodgkin's lymphoma. Such 'naked' antibodies can recruit the body's immune effector mechanisms to kill cells expressing the target of the antibody. In recent years, the linking of radionuclides to antibodies to either augment inherent activity or to exploit the specific targeting properties of monoclonal antibodies has been a major area of development. Two radionuclide-bearing monoclonal antibody therapies have recently been approved by the US FDA, and several more are in clinical trials. Here, we discuss the development and use of radiolabelled monoclonal antibody therapies, with a focus on radiolabelled monoclonal antibodies that have been evaluated in clinical trials.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
ObjectType-Review-3
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ObjectType-Feature-3
ObjectType-Review-1
ISSN:1474-1776
1474-1784
DOI:10.1038/nrd1413